N/A N=82 Femtosecond Laser-assisted Arcuate Incisions Versus Manual Arcuate Incisions Outcomes
Cataract
Primary: Residual Refractive Astigmatism — .21; .22 diopters
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=20 Evaluate the Efficiency Impact of Conducting Active Temperature Management During Cardiac Cryoablation Procedures
Atrial Fibrillation
Primary: Total Time of Active Ablation Procedure — 126 minutes
Phase 2 N=51 Feasibility Study of Metformin Therapy in ADPKD
Polycystic Kidney, Autosomal Dominant
Primary: Safety and Tolerability of Metformin — 50; 100; 82; 100 percentage of participants
Phase 3 N=60 Comparison of Sternal Wound Infiltration With Liposomal Bupivacaine v. Bupivacaine Hydrochloride
Coronary Artery Disease · Coronary Artery Stenoses · Valve Regurgitation, Mitral
Primary: Post-operative Pain Intensity — 4.7482; 5.03; 5.75; 6.64 score on a scale
N/A N=38 Measurements of Angulation of the C-spine
Cervical Spine
Primary: Measurements of Angulation of the Neck (C-spine) on MRI Scans — 10.6; 21.6; 5.5; 4.1 degrees — p=<0.001
Phase 1 N=16 Study in Blood Stage Malaria Infection After DVI of Cryopreserved P. Falciparum (NF54 Strain) Sporozoites
Malaria,Falciparum · Parasitemia · Protozoan Infections
Primary: Incidence and Severity of Observed or Self-reported Adverse Events (AEs) Considered PfSPZ-DVI Challenge Inoculum-related. — 13; 12; 1; 2 Incidence
N/A N=19 Virtual Reality vs Technical Video in Surgical Training
Surgical Training
Primary: Objective Structured Assessment of Technical Skills (OSATS) — 15.9; 9.4 score on a scale
Phase 2 N=376 Clinical Study of Meningococcal ACYWX Conjugate Vaccine, in 12-16 Month Olds
Meningitis, Meningococcal
Primary: Severe Solicited Adverse Event — 0; 0; 0; 0 participants
Phase 2 N=23 Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa
Breast Cancer
Primary: Percentages of Participants With Pathologic Complete Response — 48 percentage of participants
N/A N=121 Adaptive Design Study of NEST sTMS in Subjects With Major Depressive Disorder
Depressive Disorder · Depression · Depressive Disorder, Major
Primary: Incidence of Clinical Response (Reduction of At Least 50% in Baseline HAMD-17 Score) in Per-Protocol Population — 5; 2; 7; 10 Participants — p=.814
Phase 3 N=45 Safety Trial of OPC-61815 Injection in Patients With Congestive Heart Failure Who Have Difficulty With or Are Incapable of Oral Intake
Congestive Heart Failure
Primary: Percentage of Subjects With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs — 77.8 percentage of participants
Phase 3 N=207 A Hepatitis B Vaccine Challenge Study After Previous Vaxelis® Vaccination (V419-013)
Hepatitis B
Primary: Percentage of Participants With a Protective Hepatitis B Surface Antibody Level of ≥10 Milli International Units/mL (mIU/mL) at 30 Days Post-Challenge With HBVAXPRO™…
N/A N=187 Effects Among Smokers Who Use and Do Not Use E-Cigarettes
Toxicant Exposure
Primary: Toxicant Exposure — 40; 97 pg/ml
Phase 1 N=10 Letetresgene Autoleucel Engineered T Cells in NY-ESO -1 Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
Neoplasms
Primary: Number of Participants With Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs) — 6; 4 Participants
N/A N=100 Stigma, Risk Behaviors and Health Care Among HIV-infected Russian People Who Inject Drugs
HIV Infections · Stigmatization · Substance Use
Primary: Number of Participants Satisfied With the Intervention — 61; 0 Participants